Saltar al contenido
Merck
Todas las fotos(1)

Documentos clave

Ver Toda la documentación

1478800

USP

Orlistat

United States Pharmacopeia (USP) Reference Standard

Sinónimos:

(−)-Tetrahydrolipstatin, N-Formyl-L-leucine (1S)-1-[[(2S,3S)-3-hexyl-4-oxo-2-oxetanyl]methyl]dodecyl ester, Ro-18-0647

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización
Todas las fotos(1)

About This Item

Fórmula empírica (notación de Hill):
C29H53NO5
Número de CAS:
96829-58-2
Peso molecular:
495.73
Número MDL:
MFCD05662360
Código UNSPSC:
41116107
ID de la sustancia en PubChem:
329750618
NACRES:
NA.24

grado

pharmaceutical primary standard

familia API

orlistat

fabricante / nombre comercial

USP

aplicaciones

pharmaceutical (small molecule)

Formato

neat

cadena SMILES

CCCCCCCCCCC[C@@H](C[C@@H]1OC(=O)[C@H]1CCCCCC)OC(=O)[C@H](CC(C)C)NC=O

InChI

1S/C29H53NO5/c1-5-7-9-11-12-13-14-15-16-18-24(34-29(33)26(30-22-31)20-23(3)4)21-27-25(28(32)35-27)19-17-10-8-6-2/h22-27H,5-21H2,1-4H3,(H,30,31)/t24-,25-,26-,27-/m0/s1

Clave InChI

AHLBNYSZXLDEJQ-FWEHEUNISA-N

Información sobre el gen

human ... LIPF(8513) , PNLIP(5406)

¿Está buscando productos similares? Visita Guía de comparación de productos

Descripción general

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Aplicación

Orlistat USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia.

Acciones bioquímicas o fisiológicas

Orlistat, used in obesity research, is a pancreatic lipase inhibitor that acts locally in the gastrointestinal tract to inhibit lipase.

Nota de análisis

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

Otras notas

Solution is not completely clear, small particles may remain floating.
Sales restrictions may apply.

Producto relacionado

Referencia del producto
Descripción
Precios

1478833

Orlistat Related Compound C, United States Pharmacopeia (USP) Reference Standard

1478811

Orlistat Related Compound A, United States Pharmacopeia (USP) Reference Standard

1478844

Orlistat Related Compound D, United States Pharmacopeia (USP) Reference Standard

1478855

Orlistat Related Compound E, United States Pharmacopeia (USP) Reference Standard

1478822

Orlistat Related Compound B, United States Pharmacopeia (USP) Reference Standard

1680685

Tributyl phosphine oxide, United States Pharmacopeia (USP) Reference Standard

PHR2544

Orlistat Related Compound C, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2543

Orlistat Related Compound B, Pharmaceutical Secondary Standard; Certified Reference Material

Código de clase de almacenamiento

11 - Combustible Solids

Clase de riesgo para el agua (WGK)

WGK 3

Punto de inflamabilidad (°F)

Not applicable

Punto de inflamabilidad (°C)

Not applicable

Elija entre una de las versiones más recientes:

Certificados de análisis (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documentos section.

Si necesita más asistencia, póngase en contacto con Atención al cliente

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Theodosios D Filippatos et al.
Drug safety, 31(1), 53-65 (2007-12-22)
Orlistat, an anti-obesity drug, is a potent and specific inhibitor of intestinal lipases. In light of the recent US FDA approval of the over-the-counter sale of orlistat (60 mg three times daily), clinicians need to be aware that its use
Belinda S Drew et al.
Vascular health and risk management, 3(6), 817-821 (2008-01-19)
Over the past 20 years obesity has become a worldwide concern of frightening proportion. The World Health Organization estimates that there are over 400 million obese and over 1.6 billion overweight adults, a figure which is projected to almost double
[Pharmacological sheet. Orlistat, oral administration (Xenical, Alli). ].
Journal de pharmacie de Belgique, (2)(2), 67-68 (2009-09-11)
J-P Chaput et al.
Mini reviews in medicinal chemistry, 7(1), 3-10 (2007-02-03)
The currently available drugs for long-term treatment of obesity are sibutramine and orlistat. They have been shown to be able to induce significant weight loss, with important co-morbidity reduction, allowing the maintenance of reduced body weight for at least 1-2
E García Díaz et al.
Nutricion hospitalaria, 26(3), 451-457 (2011-09-06)
The prevalence of obesity, a serious public health problem, is increasing among teenagers and thus also increases cardiovascular morbidity and mortality in adulthood. To provide a systematic review of the best evidence about the effect of sibutramine and orlistat in
Ver todos los artículos relacionados

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico